At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 22 enrolled
Drug / intervention
Modafinil +1 moredrug
Likely dose
Modafinil 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Apathy in Alzheimer's Disease With Modafinil
In Brief
A Phase 3 clinical trial evaluating Modafinil and Placebo for Apathy and Alzheimer's Disease. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsApathy, Alzheimer's Disease
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Cephalon
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
Study CompletionSep 2007
First PostedJul 2010
TodayJul 2026
First PostedJul 29, 2010
Enrollment StartJul 1, 2005
Study CompletionSep 1, 2007
TodayJul 2, 2026
Posted 15.9 years ago
Interventions
Modafinildrug
100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
Placebodrug
100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks